These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 12846891)
1. Valpha24+ natural killer T-cell responses against T-acute lymphoblastic leukaemia cells: implications for immunotherapy. Takahashi T; Haraguchi K; Chiba S; Yasukawa M; Shibata Y; Hirai H Br J Haematol; 2003 Jul; 122(2):231-9. PubMed ID: 12846891 [TBL] [Abstract][Full Text] [Related]
2. Human invariant valpha24+ natural killer T cells activated by alpha-galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells. Nicol A; Nieda M; Koezuka Y; Porcelli S; Suzuki K; Tadokoro K; Durrant S; Juji T Immunology; 2000 Feb; 99(2):229-34. PubMed ID: 10692041 [TBL] [Abstract][Full Text] [Related]
3. Cutting edge: analysis of human V alpha 24+CD8+ NK T cells activated by alpha-galactosylceramide-pulsed monocyte-derived dendritic cells. Takahashi T; Chiba S; Nieda M; Azuma T; Ishihara S; Shibata Y; Juji T; Hirai H J Immunol; 2002 Apr; 168(7):3140-4. PubMed ID: 11907064 [TBL] [Abstract][Full Text] [Related]
4. The characteristics of human NKT cells in lung cancer--CD1d independent cytotoxicity against lung cancer cells by NKT cells and decreased human NKT cell response in lung cancer patients. Konishi J; Yamazaki K; Yokouchi H; Shinagawa N; Iwabuchi K; Nishimura M Hum Immunol; 2004 Nov; 65(11):1377-88. PubMed ID: 15556688 [TBL] [Abstract][Full Text] [Related]
5. Insufficient ex vivo expansion of Valpha24(+) natural killer T cells in malignant lymphoma patients related to the suppressed expression of CD1d molecules on CD14(+) cells. Imataki O; Heike Y; Makiyama H; Iizuka A; Ikarashi Y; Ishida T; Wakasugi H; Takaue Y Cytotherapy; 2008; 10(5):497-506. PubMed ID: 18608348 [TBL] [Abstract][Full Text] [Related]
6. Expansion of alpha-galactosylceramide-stimulated Valpha24+ NKT cells cultured in the absence of animal materials. Harada Y; Imataki O; Heike Y; Kawai H; Shimosaka A; Mori S; Kami M; Tanosaki R; Ikarashi Y; Iizuka A; Yoshida M; Wakasugi H; Saito S; Takaue Y; Takei M; Kakizoe T J Immunother; 2005; 28(4):314-21. PubMed ID: 16000949 [TBL] [Abstract][Full Text] [Related]
7. Dendritic cells are targets for human invariant Valpha24+ natural killer T-cell cytotoxic activity: an important immune regulatory function. Nicol A; Nieda M; Koezuka Y; Porcelli S; Suzuki K; Tadokoro K; Durrant S; Juji T Exp Hematol; 2000 Mar; 28(3):276-82. PubMed ID: 10720692 [TBL] [Abstract][Full Text] [Related]
8. [Ex vivo expansion of Valpha24 natural killer T cells with alpha-galactosylceramide]. Huang Y; Jiang EL; Zhou Z; He Y; Wang M; Liu QG; Zhai WJ; Han MZ Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Jun; 27(3):315-20. PubMed ID: 16038267 [TBL] [Abstract][Full Text] [Related]
9. In vitro anti-tumour activity of alpha-galactosylceramide-stimulated human invariant Valpha24+NKT cells against melanoma. Kikuchi A; Nieda M; Schmidt C; Koezuka Y; Ishihara S; Ishikawa Y; Tadokoro K; Durrant S; Boyd A; Juji T; Nicol A Br J Cancer; 2001 Sep; 85(5):741-6. PubMed ID: 11531261 [TBL] [Abstract][Full Text] [Related]
10. Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells. van der Vliet HJ; Molling JW; Nishi N; Masterson AJ; Kölgen W; Porcelli SA; van den Eertwegh AJ; von Blomberg BM; Pinedo HM; Giaccone G; Scheper RJ Cancer Res; 2003 Jul; 63(14):4101-6. PubMed ID: 12874013 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Nieda M; Okai M; Tazbirkova A; Lin H; Yamaura A; Ide K; Abraham R; Juji T; Macfarlane DJ; Nicol AJ Blood; 2004 Jan; 103(2):383-9. PubMed ID: 14512316 [TBL] [Abstract][Full Text] [Related]
12. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. Metelitsa LS; Naidenko OV; Kant A; Wu HW; Loza MJ; Perussia B; Kronenberg M; Seeger RC J Immunol; 2001 Sep; 167(6):3114-22. PubMed ID: 11544296 [TBL] [Abstract][Full Text] [Related]
13. A subset of NKT cells that lacks the NK1.1 marker, expresses CD1d molecules, and autopresents the alpha-galactosylceramide antigen. Hameg A; Apostolou I; Leite-De-Moraes M; Gombert JM; Garcia C; Koezuka Y; Bach JF; Herbelin A J Immunol; 2000 Nov; 165(9):4917-26. PubMed ID: 11046017 [TBL] [Abstract][Full Text] [Related]
14. Potent expansion of human natural killer T cells using alpha-galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15. van der Vliet HJ ; Nishi N; Koezuka Y; von Blomberg BM ; van den Eertwegh AJ ; Porcelli SA; Pinedo HM; Scheper RJ; Giaccone G J Immunol Methods; 2001 Jan; 247(1-2):61-72. PubMed ID: 11150537 [TBL] [Abstract][Full Text] [Related]
15. Human invariant V alpha 24-J alpha Q TCR supports the development of CD1d-dependent NK1.1+ and NK1.1- T cells in transgenic mice. Capone M; Cantarella D; Schümann J; Naidenko OV; Garavaglia C; Beermann F; Kronenberg M; Dellabona P; MacDonald HR; Casorati G J Immunol; 2003 Mar; 170(5):2390-8. PubMed ID: 12594262 [TBL] [Abstract][Full Text] [Related]
16. Circulating Valpha24+Vbeta11+ NKT cell numbers and dendritic cell CD1d expression in hepatitis C virus infected patients. van der Vliet HJ; Molling JW; von Blomberg BM; Kölgen W; Stam AG; de Gruijl TD; Mulder CJ; Janssen HL; Nishi N; van den Eertwegh AJ; Scheper RJ; van Nieuwkerk CJ Clin Immunol; 2005 Feb; 114(2):183-9. PubMed ID: 15639652 [TBL] [Abstract][Full Text] [Related]
17. CD1d-restricted human natural killer T cells are highly susceptible to human immunodeficiency virus 1 infection. Motsinger A; Haas DW; Stanic AK; Van Kaer L; Joyce S; Unutmaz D J Exp Med; 2002 Apr; 195(7):869-79. PubMed ID: 11927631 [TBL] [Abstract][Full Text] [Related]
18. Increased infiltration of CD1d and natural killer T cells in periodontal disease tissues. Amanuma R; Nakajima T; Yoshie H; Yamazaki K J Periodontal Res; 2006 Feb; 41(1):73-9. PubMed ID: 16409258 [TBL] [Abstract][Full Text] [Related]
19. Preserved IFN-alpha production of circulating Valpha24 NKT cells in primary lung cancer patients. Motohashi S; Kobayashi S; Ito T; Magara KK; Mikuni O; Kamada N; Iizasa T; Nakayama T; Fujisawa T; Taniguchi M Int J Cancer; 2002 Nov; 102(2):159-65. PubMed ID: 12385012 [TBL] [Abstract][Full Text] [Related]
20. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Motohashi S; Ishikawa A; Ishikawa E; Otsuji M; Iizasa T; Hanaoka H; Shimizu N; Horiguchi S; Okamoto Y; Fujii S; Taniguchi M; Fujisawa T; Nakayama T Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6079-86. PubMed ID: 17028247 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]